{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shanley M"],"funding":["NHLBI NIH HHS","NCI NIH HHS","NIH HHS"],"pagination":["1450-1466.e11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11370652"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(8)"],"pubmed_abstract":["Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control. IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 "],"journal":["Cancer cell"],"pubmed_title":["Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD."],"pmcid":["PMC11370652"],"funding_grant_id":["U01 CA247760","S10 OD024977","P30 CA016672","R35 HL144805","P50 CA127001"],"pubmed_authors":["Miao Q","Mohanty V","Evans SE","Fowlkes NW","Nunez Cortes AK","Dede M","Zaman MF","Zhang P","Lang FF","Rafei H","Shpall EJ","Daher M","Acharya S","Jain A","Shanley M","Gumin J","Singh S","Chen K","Dou J","Pantaleοn Garcιa J","Hicks SC","Uprety N","Jones CM","He S","Li Y","Li S","Basar R","Deyter GM","Rezvani K","Liu B","Xiong D","Shaim H","Liu E","Muniz-Feliciano L"],"additional_accession":[]},"is_claimable":false,"name":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.","description":"Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control. IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-05-29T17:57:52.062Z","creation":"2026-05-18T03:07:41.973Z"},"accession":"S-EPMC11370652","cross_references":{"pubmed":["39137729"],"doi":["10.1016/j.ccell.2024.07.007"]}}